ZIOPHARM ONCOLOGY (ZIOP)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

Annual Reports

Quarterly Reports

8-K

8-K (Jan 8, 2013)8-K (Nov 8, 2012)8-K (Oct 19, 2012)8-K (Sep 7, 2012)8-K (Aug 2, 2012)8-K (Jul 17, 2012)8-K (Jun 26, 2012)8-K (Jun 19, 2012)8-K (Jun 4, 2012)8-K (May 10, 2012)8-K (May 3, 2012)8-K (Apr 3, 2012)8-K (Apr 2, 2012)8-K (Feb 29, 2012)8-K (Feb 14, 2012)8-K (Jan 25, 2012)8-K (Jan 20, 2012)8-K (Jan 11, 2012)8-K (Dec 22, 2011)8-K (Dec 7, 2011)8-K (Nov 15, 2011)8-K (Nov 3, 2011)8-K (Oct 28, 2011)8-K (Sep 6, 2011)8-K (Aug 1, 2011)8-K (Jul 15, 2011)8-K (Jun 22, 2011)8-K (Jun 10, 2011)8-K (Jun 6, 2011)8-K (Jun 3, 2011)8-K (May 23, 2011)8-K (May 19, 2011)8-K (May 13, 2011)8-K (May 9, 2011)8-K (May 5, 2011)8-K (Mar 7, 2011)8-K (Mar 1, 2011)8-K (Feb 8, 2011)8-K (Feb 7, 2011)8-K (Feb 3, 2011)8-K (Jan 26, 2011)8-K (Jan 12, 2011)8-K (Jan 5, 2011)8-K (Dec 28, 2010)8-K (Nov 12, 2010)8-K (Nov 4, 2010)8-K (Sep 27, 2010)8-K (Sep 23, 2010)8-K (Jul 30, 2010)8-K (Jul 20, 2010)8-K (Jun 23, 2010)8-K (Jun 21, 2010)8-K (Jun 7, 2010)8-K (Jun 2, 2010)8-K (May 21, 2010)8-K (Apr 30, 2010)8-K (Apr 6, 2010)8-K (Mar 18, 2010)8-K (Jan 27, 2010)8-K (Dec 8, 2009)8-K (Nov 12, 2009)8-K (Nov 6, 2009)8-K (Oct 14, 2009)8-K (Sep 15, 2009)8-K (Aug 14, 2009)8-K (Jun 4, 2009)8-K (Jun 1, 2009)8-K (May 15, 2009)8-K (Mar 24, 2009)8-K (Dec 8, 2008)8-K (Nov 17, 2008)8-K (Oct 31, 2008)8-K (Oct 23, 2008)8-K (Oct 15, 2008)8-K (Oct 8, 2008)8-K (Sep 8, 2008)8-K (Aug 19, 2008)8-K (Aug 4, 2008)8-K (Jul 31, 2008)8-K (Jul 23, 2008)8-K (Jun 30, 2008)8-K (Jun 20, 2008)8-K (May 13, 2008)8-K (May 12, 2008)8-K (May 9, 2008)8-K (Apr 23, 2008)8-K (Apr 16, 2008)8-K (Mar 20, 2008)8-K (Jan 23, 2008)8-K (Dec 18, 2007)8-K (Nov 29, 2007)8-K (Nov 6, 2007)8-K (Oct 25, 2007)8-K (Sep 26, 2007)8-K (Sep 11, 2007)8-K (Jul 9, 2007)8-K (Jun 19, 2007)8-K (Feb 26, 2007)8-K (Feb 16, 2007)8-K (Jan 18, 2007)8-K (Jan 16, 2007)8-K (Jan 9, 2007)8-K (Dec 26, 2006)8-K (Nov 13, 2006)8-K (Nov 6, 2006)8-K (Nov 3, 2006)8-K (Oct 3, 2006)8-K (Sep 20, 2006)8-K (May 3, 2006)8-K (Apr 26, 2006)8-K (Dec 20, 2005)8-K (Sep 19, 2005)8-K (Aug 24, 2005)8-K (Aug 9, 2005)

Other

ZIOPHARM ONCOLOGY 8-K 2012

Documents found in this filing:

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 29, 2012

ZIOPHARM Oncology, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-33038

84-1475672

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

1180 Avenue of the Americas 19^th Floor New York, NY		10036
(Address of Principal Executive Offices)		(Zip Code)

(646) 214-0700

(Registrant’s telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 8.01

Other Events

On February 29, 2012, ZIOPHARM Oncology, Inc. issued a press release announcing its financial condition and results of operations for the fourth quarter and year ended December 31, 2011. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01	Financial Statements and Exhibits

(d)	Exhibits

	Exhibit No.	Description

	99.1	Press Release of the Company dated February 29, 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ZIOPHARM Oncology, Inc.


	By:	/s/ Richard Bagley
Date: February 29, 2012		Name: Richard Bagley
		Title: President, Chief Operating Officer and Chief Financial Officer

INDEX OF EXHIBITS

Exhibit No.		Description

99.1		Press Release of the Company dated February 29, 2012

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.

Mobile | Advertise | Licensing & Partnerships | Blogger Tools | Jobs

ZIOPHARM ONCOLOGY (ZIOP)

Annual Reports

Quarterly Reports

8-K

Other

Documents found in this filing: